Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May;11(5):698-701.
doi: 10.4103/1673-5374.182681.

TFP5/TP5 peptide provides neuroprotection in the MPTP model of Parkinson's disease

B K Binukumar  1 , Harish C Pant  1
Affiliations
Review

TFP5/TP5 peptide provides neuroprotection in the MPTP model of Parkinson's disease

B K Binukumar et al. Neural Regen Res. 2016 May.

Abstract

Cyclin-dependent kinase 5 (Cdk5) is a member of the serine-threonine kinase family of cyclin-dependent kinases. Cdk5 is critical to normal mammalian nervous system development and plays important regulatory roles in multiple cellular functions. Recent evidence indicates that Cdk5 is inappropriately activated in several neurodegenerative conditions, including Parkinson's disease (PD). PD is a chronic neurodegenerative disorder characterized by the loss of dopamine neurons in the substantia nigra, decreased striatal dopamine levels, and consequent extrapyramidal motor dysfunction. During neurotoxicity, p35 is cleaved to form p25. Binding of p25 with Cdk5 leads deregulation of Cdk5 resulting in number of neurodegenerative pathologies. To date, strategies to specifically inhibit Cdk5 hyperactivity have not been successful without affecting normal Cdk5 activity. Here we show that inhibition of p25/Cdk5 hyperactivation through TFP5/TP5, truncated 24-aa peptide derived from the Cdk5 activator p35 rescues nigrostriatal dopaminergic neurodegeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP/MPP(+)) in a mouse model of PD. TP5 peptide treatment also blocked dopamine depletion in the striatum and improved gait dysfunction after MPTP administration. The neuroprotective effect of TFP5/TP5 peptide is also associated with marked reduction in neuroinflammation and apoptosis. Here we show inhibition of Cdk5/p25-hyperactivation by TFP5/TP5 peptide, which identifies Cdk5/p25 as a potential therapeutic target to reduce neurodegeneration in PD.

Keywords: MPTP; Parkinson's disease; TP5 TFP5/TP5 peptide; cyclin-dependent kinase 5; neurodegeneration; therapeutic target.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors declare no competing financial interests.

References

    1. Alvira D, Tajes M, Verdaguer E, Acuña-Castroviejo D, Folch J, Camins A, Pallas M. Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease. J Pineal Res. 2006;40:251–258. - PubMed
    1. Amin ND, Albers W, Pant HC. Cyclin-dependent kinase 5 (cdk5) activation requires interaction with three domains of p35. J Neurosci Res. 2002;67:354–362. - PubMed
    1. Avraham E, Rott R, Liani E, Szargel R, Engelender S. Phosphorylation of parkin by the cyclin-dependent kinase 5 at the linker region modulates the E3 ubiquitin-ligase activity and parkin aggregation. J Biol Chem. 2007;282:12842–12850. - PubMed
    1. Bajaj NP, Al-Sarraj ST, Anderson V, Kibble M. Cyclin-dependent kinase-5 is associated with lipofuscin in motor neurones in amyotrophic lateral sclerosis. Neurosci Lett. 1998;245:45–48. - PubMed
    1. Bajaj NP, al-Sarraj ST, Leigh PN, Anderson V, Miller CC. Cyclin dependent kinase-5 (CDK-5) phosphorylates neurofilaments heavy (NF-H) chain to generate epitopes for antibodies that label neurofilament accumulations in amyotrophic lateral sclerosis (ALS) and is present in affected motor neurones in ALS. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23:833–850. - PubMed